Clinical trial
Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth
NCT00102960 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00102960 |
|---|---|
| Title | Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth |
| Official title | A Phase III, Randomized, Open-Label Trial to Evaluate Strategies for Providing Antiretroviral Therapy to Infants Shortly After Primary Infection in a Resource Poor Setting |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Abacavir sulfate, Didanosine, Efavirenz, Lamivudine, Lopinavir/Ritonavir, Nevirapine, Zidovudine |
| Enrollment | 377 |
| Start date | Jul 1, 2005 |
| Primary completion | Sep 1, 2012 |
| Completion | Jan 1, 2013 |
| First posted | Feb 7, 2005 |
| Last update posted | Nov 2, 2021 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: